Table 1. Associations of ATM (rs1801516) and ERCC5 (rs1047768) polymorphisms with PFS.
| n | Median PFS in months (95% CI) | Univariate HR (95% CI)a | P a | Multivariate HR (95% CI)a,b | P a , b | |
|---|---|---|---|---|---|---|
| ATM rs1801516 | ||||||
| Wild type | 371 | 9.1 (8.3–10.4) | 1 | — | 1 | — |
| Heterozygote | 127 | 12.4 (9.6–13.5) | 0.88 (0.70–1.09) | 0.245 | 0.93 (0.75–1.17) | 0.543 |
| Homozygote mutant | 8 | 11.8 (7.2-∞)c | 0.61 (0.27–1.36) | 0.225 | 0.94 (0.42–2.12) | 0.881 |
| ERCC5 rs1047768 | ||||||
| Wild type | 180 | 10.6 (9.1–12.5) | 1 | — | 1 | — |
| Heterozygote | 267 | 9.2 (8.2–10.6) | 1.13 (0.93–1.39) | 0.227 | 1.15 (0.93–1.42) | 0.194 |
| Homozygote mutant | 77 | 10.1 (8.5–12.2) | 0.96 (0.72–1.29) | 0.797 | 0.94 (0.69–1.28) | 0.689 |
Abbreviations: ATM=ataxia telangiectasia mutated; CI=confidence interval; ERCC5=excision repair cross-complementing group 5; HR=hazard ratios; PFS=progression-free survival.
a
HR, 95% CI and P-values computed using a Cox proportional hazards model with the wild type as reference.
b
Covariates included in the multivariate model: age, gender, serum LDH (normal vs above normal) and treatment arm (oxaliplatin, capecitabine and bevacizumab vs oxaliplatin, capecitabine, bevacizumab and cetuximab).
c
The upper limit of the 95% CI for PFS of the ATM homozygote mutants could not be estimated because of the low number of patients.